Low-Cost HIV Alliance To Restore GSK’s China Image?
This article was originally published in PharmAsia News
Although it is still awaiting approval from the China FDA for its widely-sold and fast-growing HIV drug, GSK unit ViiV has linked a deal with a Chinese firm to manufacture low-priced Tivicay in the country. The arrangement could be a preemptive move as China is increasing pressure on the prices of costly new therapies for infectious diseases.
You may also be interested in...
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.